TLR2 and acute respiratory distress syndrome: Sung and colleagues [129] demonstrated that SARS-CoV-2-activated platelets produced extracellular vesicles that enhanced thrombo-inflammation via the C-type lectin member 5A and TLR2, suggesting that TLR2 may represent a potential therapeutic target to reduce the risk of acute respiratory distress syndrome in COVID-19 patients.